Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Risk genes beyond APOE

Topic: Risk, prevention and care in population studies

KEY POINTSO_LIThis paper demonstrates the feasibility of implementing Geriatric ED programs with targeted support for people living with or at risk for dementia across three distinct health systems in San Francisco. We describe the reach and implementation processes of each program including commonalities, differences, challenges faced, and opportunities for future improvement. C_LIO_LICreating unique care pathways for older adults and those with cognitive impairment in the emergency department (ED) is often guided by health system resources. C_LIO_LIAssessing cognition and identifying potential dementia is feasible during an ED visit. C_LIO_LIAn interprofessional approach to geriatric ED care is essential to sustainability and success.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hauser, K. A., Degesys, N. F., Isaacs, E. D., Tang, M., Swartzberg, J., Panopulos, V., et al. (2026). Enhancing Emergency Care for Persons Living with Dementia: Innovation and Age-friendly Approaches in Three Emergency Departments. medRxiv (preprint). https://doi.org/10.64898/2026.08.19.26360807

Vancouver

Hauser KA, Degesys NF, Isaacs ED, Tang M, Swartzberg J, Panopulos V, et al. Enhancing Emergency Care for Persons Living with Dementia: Innovation and Age-friendly Approaches in Three Emergency Departments. medRxiv (preprint). 2026. doi:10.64898/2026.08.19.26360807.

BibTeX

@article{hauser2026-a23f2332,
  author  = {Hauser, K. A. and Degesys, N. F. and Isaacs, E. D. and Tang, M. and Swartzberg, J. and Panopulos, V. and Martin, A. M. and Liu and others},
  title   = {{Enhancing Emergency Care for Persons Living with Dementia: Innovation and Age-friendly Approaches in Three Emergency Departments}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.08.19.26360807},
  url     = {https://doi.org/10.64898/2026.08.19.26360807}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This paper describes implementing Geriatric Emergency Department programs with targeted support for people living with or at risk for dementia across three health systems. It addresses emergency care delivery and feasibility, not the treatment, cure or prevention of Alzheimer's disease itself.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 21 of the 94 points it could be judged on, which is 22 of 100. Raw total 22 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 22 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 22 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 21 of the 94 points we could judge it on, which is 22 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Ula Hwang: h-index 44 (OpenAlex, whole career)
Institution's track record 2 / 3 Yale University: institution h-index 1,927 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 21 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 21 of the 94 points we could judge it on is 22 out of 100.
Total 22 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Risk genes beyond APOE

Also tagged “prevalence”

1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →